Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea
Basketball legend, entrepreneur and entertainer
Moderate-to-severe obstructive sleep apnea (OSA) is a serious, often underdiagnosed health condition that affects an estimated 24 million adults in the
"Moderate-to-severe obstructive sleep apnea is more than just snoring – it's a serious condition and it deserves serious attention," O'Neal shared. "For years, I was tired all the time and didn't know why, but getting diagnosed made a real difference. I'm not always one to ask for help, and I know it can be difficult to speak up when something is impacting you. I'm here to say don't ignore moderate-to-severe OSA symptoms – talk to your doctor."
Symptoms and Impacts: Why Addressing Moderate-to-Severe OSA Matters
People with moderate-to-severe OSA may not get the necessary oxygen due to an airway that is partially or fully blocked at times during sleep3. Those with moderate OSA, like Shaquille, may experience breathing interruptions 15-29 times per hour, while 30 or more interruptions an hour may indicate severe OSA3. Risk factors for moderate-to-severe OSA include being of the male sex, obesity, being over the age of 50 and having a family history of OSA4 5 6. In addition to breathing disruptions during sleep, moderate-to-severe OSA can also cause daytime sleepiness and reduced concentration.
"Moderate-to-severe obstructive sleep apnea is a serious and often overlooked condition that affects millions of Americans," said
Talk to your doctor about OSA if you experience symptoms including loud snoring, choking and/or gasping for air while sleeping, daytime sleepiness, fatigue or irritability.
To learn more about symptoms and risk factors for moderate-to-severe OSA in adults with obesity, as well as tools for speaking to your doctor, visit DontSleepOnOSA.com.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. C-LLY
|
Refer to: |
|
|
|
|
|
|
|
|
1 |
Benjafield AV, Ayas NT, Eastwood PR, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019;7(8):687-698. |
|
2 |
Young T, Peppard PE, Taheri S. Excess weight and sleep-disordered breathing. J Appl Physiol. 2005;99(4):1592-1599. |
|
3 |
Gottlieb DJ, Punjabi NM. Diagnosis and management of obstructive sleep apnea: a review. JAMA. 2020;323(14):1389-1400. |
|
4 |
Chang JL, Goldberg AN, Alt JA, et al. International consensus statement on obstructive sleep apnea. Int Forum Allergy Rhinol. 2023;13(7):1061-1482. |
|
5 |
Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive sleep apnea and cardiovascular disease: a scientific statement from the |
|
6 |
Abbasi A, Gupta SS, Sabharwal N, et al. A comprehensive review of obstructive sleep apnea. Sleep Sci. 2021;14(2):142-154. |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-drafts-shaquille-oneal-to-raise-awareness-for-moderate-to-severe-obstructive-sleep-apnea-302594368.html
SOURCE